Modern Chinese Medicine Group Co., Ltd. (SEHK: 1643)
Health Care · Pharmaceuticals · CN
HK$0.84
-0.59% today · +35.5% 1Y
Modern Chinese Medicine Group Co., Ltd. (SEHK: 1643) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $77.07M and employs 189 people.
Over the last twelve months the share price has gained 35.5%, trading between 0.49 and 3.26.
Tweenvest scores Modern Chinese Medicine Group Co., Ltd. across four factors: quality 65/100, value 9/100, growth 0/100. Its strongest factor is quality.
1643 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $77.07M
- Revenue (TTM)
- $20.76M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.19
- 52-week high
- HK$3.26
- 52-week low
- HK$0.49
- Avg volume (3M)
- —
- Shares outstanding
- 720.00M
- Employees
- 189
- Next earnings
- —
About Modern Chinese Medicine Group Co., Ltd.
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
- ISIN
- KYG6181B1068
- Founded
- 1986
- Listed since
- Jan 15, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.